^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CBFB-MYH11 fusion

    i
    Other names: CBFB, Core-Binding Factor Subunit Beta 2, SL3/AKV Core-Binding Factor Beta Subunit, SL3-3 Enhancer Factor 1 Subunit Beta, Core-Binding Factor Beta Subunit, PEBP2-Beta, PEA2-Beta, CBF-Beta, PEBP2B, Polyomavirus Enhancer Binding Protein 2, Beta Subunit, Polyomavirus Enhancer-Binding Protein 2 Beta Subunit, SL3-3 Enhancer Factor 1 Beta Subunit, Core-Binding Factor, Beta Subunit, CBFB, MYH11, Myosin Heavy Chain 11, SMMHC, Myosin, Heavy Polypeptide 11, Smooth Muscle, Myosin Heavy Chain, Smooth Muscle
    Related tests:
    Apply
    Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) (NCT02013648)
    Phase 3
    University of Ulm
    Completed
    Last update posted :
    02/23/2024
    Initiation :
    07/01/2014
    Primary completion :
    02/01/2024
    Completion :
    02/01/2024
    RUNX1 • RUNX1T1
    |
    RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion
    |
    dasatinib • daunorubicin • idarubicin hydrochloride
    Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor (RETRO-CBF) (NCT05070208)
    Phase N/A
    Acute Leukemia French Association
    Completed
    Last update posted :
    01/31/2024
    Initiation :
    09/22/2021
    Primary completion :
    01/25/2024
    Completion :
    01/25/2024
    RUNX1 • RUNX1T1
    |
    RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion
    Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01238211)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    03/01/2023
    Initiation :
    12/14/2010
    Primary completion :
    07/01/2013
    Completion :
    03/15/2021
    RUNX1 • RUNX1T1
    |
    RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion
    |
    dasatinib • cytarabine • daunorubicin • Starasid (cytarabine ocfosfate)